Relay Therapeutics (RLAY) Competitor Comparison
We are evaluating the key criteria listed to compare Relay Therapeutics (RLAY) against its competitors in the Biotechnology industry.
Market Capitalization
108 / 368Gross Profits
124 / 278Total Revenue
147 / 300EBITDA
312 / 337Free Cashflow
316 / 352Quick Ratio
40 / 357Earnings per Share
244 / 359Dividend yield
0 / 6Total Cash
33 / 358Performance 3 years
253 / 368Performance 5 years
243 / 368Performance 10 years
216 / 368Linearity 3 years
190 / 368Linearity 5 years
169 / 368Linearity 10 years
170 / 368Total Rank
248 / 368Dividend Rank
259 / 368Valuation Rank
160 / 368Piotroski Rank
309 / 368Muliplier Rank
194 / 368Total Cash - RLAY ranking 33 / 358
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.